ARGX · Healthcare
Argenx Se
25/100
Smart-money confidence1 of 3 sources positive
Weak — few signals
No standout activity across the feeds we track.
Hedge funds
34
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$65.0B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About ARGENX SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN,…
Who's behind the signal
Every informed buyer we can see on ARGX, across all three feeds.
Hedge funds · 6
Baillie Gifford & Co
New position
Millennium Management (Englander)
Increased +20%
Bridgewater Associates (Dalio)
Increased +61%
AQR Capital Management
Increased +322%
Citadel Advisors
Decreased −3%
D.E. Shaw & Co
Decreased −84%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Congressional trades · 2 on record
Disclosures from 2023-07-10 to 2026-03-30
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2026-03-30 | Alan Armstrong · R-OK | Senate | Bought | $1,001 - $15,000 |
| 2023-07-10 | Daniel S. Goldman · D-NY | House | Sold | $1,001 - $15,000 |
Not a model pick — but on our radar.
ARGENX SE isn't in the top-10 model right now, but 6 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
6
Investors
1
New positions
3
Increasing
2
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.4×
% of portfolio
0.0%
Position change
NEW
0.0% of Baillie Gifford & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+20%
0.0% of Millennium Management's portfolio
Trust weight: 1.3×
% of portfolio
0.0%
Position change
+61%
0.0% of Bridgewater Associates's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+322%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.0×
% of portfolio
0.1%
Position change
−3%
0.1% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−84%
0.0% of D.E. Shaw & Co's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to ARGENX SE
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell ARGENX SE or any security.
Get the Weekly Update
Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime